<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783857</url>
  </required_header>
  <id_info>
    <org_study_id>FMCH-2021-29672</org_study_id>
    <secondary_id>R01HD100418</secondary_id>
    <nct_id>NCT04783857</nct_id>
  </id_info>
  <brief_title>Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children</brief_title>
  <official_title>Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to address the following specific aims:&#xD;
&#xD;
        -  Determine the efficacy of Prog/DMPA in preventing postpartum smoking relapse and&#xD;
           reducing smoking relapse risk factors.&#xD;
&#xD;
        -  Examine the effects of this maternal smoking intervention on infant health.&#xD;
&#xD;
        -  Examine racial and ethnic differences in intervention outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Good Clinical Practice aligned, double-blind, placebo-controlled, randomized clinical&#xD;
      trial will be implemented by an experienced, transdisciplinary, and productive team of&#xD;
      investigators from two sites to enhance the diversity of the study sample and&#xD;
      generalizability of results. The investigators will enroll healthy pregnant women (n=312)&#xD;
      with a recent history of smoking and a desire to remain abstinent after childbirth. Using a&#xD;
      2×2 factorial design, participants will be randomized into one of four assignments: (1)&#xD;
      Prog+DMPA, (2) Prog+placebo, (3) placebo+DMPA, and (4) placebo+placebo. Using procedures&#xD;
      successfully implemented in our pilot study, participants will begin the 13-week study&#xD;
      medication four days after childbirth. Participants will be followed for nine months with&#xD;
      home/clinic visits, self-administered surveys, and self-collection of dried blood spots to&#xD;
      measure hormones and smoking-related biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">June 2, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postpartum Smoking Relapse</measure>
    <time_frame>12 weeks</time_frame>
    <description>Outcome is reported as the number of days postpartum to smoking relapse.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse-Related Risk Factors: Craving</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants are asked to rate their craving for tobacco on a scale from 0 to 4, with higher scores indicating greater craving.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant State of Health Questionnaire (ISHQ)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Infant State of Health Questionnaire (ISHQ) contains 28 items rated on a scale from 0 (not ill) to 4 (severely ill). Total scores range from 0 to 19 with higher scores indicating worse infant health.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Smoking</condition>
  <condition>Smoking Cessation</condition>
  <condition>Smoking Reduction</condition>
  <arm_group>
    <arm_group_label>Progesterone + DMPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive progesterone plus depot medroxyprogesterone acetate (DMPA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive progesterone plus the placebo injection treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + DMPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive the placebo oral pill treatment plus depot medroxyprogesterone acetate (DMPA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants in this group will receive the placebo oral pill and injection treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone 200 MG Oral Capsule</intervention_name>
    <description>Progesterone, 200mg, once daily, oral tablet/capsule</description>
    <arm_group_label>Progesterone + DMPA</arm_group_label>
    <arm_group_label>Progesterone + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depot-Medroxyprogestereone Acetate</intervention_name>
    <description>Depot medroxyprogesterone acetate intramuscular injection, once every 12 weeks</description>
    <arm_group_label>Placebo + DMPA</arm_group_label>
    <arm_group_label>Progesterone + DMPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo oral tablet, once per day</description>
    <arm_group_label>Placebo + DMPA</arm_group_label>
    <arm_group_label>Placebo + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Injection</intervention_name>
    <description>Placebo intramuscular injection, once every 12 weeks</description>
    <arm_group_label>Placebo + Placebo</arm_group_label>
    <arm_group_label>Progesterone + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  stable physical and mental health with confirmed, uncomplicated pregnancy at&#xD;
             gestational week 30-35&#xD;
&#xD;
          -  established prenatal care with written approval to participate fully in the study from&#xD;
             their prenatal healthcare provider&#xD;
&#xD;
          -  self-report of a minimum of 4 weeks of smoking abstinence with confirmation of acute&#xD;
             abstinence by expired carbon monoxide level of ≤ 5 ppm at the time of enrollment&#xD;
&#xD;
          -  history of ≥ 5 cigarettes a day for at least 6 out of the last 12 months&#xD;
&#xD;
          -  self-report of motivation to remain abstinent after delivery ≥ 7 on a 10 point&#xD;
             Likert-type scale&#xD;
&#xD;
          -  willingness to use non-hormonal contraceptives postpartum if sexually active until 12&#xD;
             weeks postpartum&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current use of tobacco products (e.g., cigars, e-cigs), nicotine replacement therapy&#xD;
             or smoking cessation medications&#xD;
&#xD;
          -  current major depressive disorder based on the Structured Clinical Interview for DSM-5&#xD;
             (SCID)&#xD;
&#xD;
          -  contraindication to progesterone treatment (e.g., current use of drugs that may&#xD;
             inhibit CYP3A4; current or history of deep vein thrombosis, pulmonary embolus,&#xD;
             clotting or bleeding disorder, hypertension, stroke, heart disease, or liver&#xD;
             dysfunction or disease; or peanut allergy)&#xD;
&#xD;
          -  contraindications to DMPA treatment (e.g., current use of aminoglutethimide or&#xD;
             planning to become pregnant in the next year)&#xD;
&#xD;
          -  current use of illicit drugs or alcohol abuse&#xD;
&#xD;
          -  treatment for illicit drug use or alcohol use disorder within the last 3 months&#xD;
&#xD;
          -  any condition that, in the opinion of the clinical team, precludes participation in&#xD;
             the trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Allen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Harrison, MPH</last_name>
    <phone>612-624-5377</phone>
    <email>harr0644@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Allen, PhD, MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Harrison, MPH</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

